-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA PRESENTED NEW BIOMARKER DATA FROM THE IMPALA-2 PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE AMERICAN THORACIC SOCIETY (ATS) INTERNATIONAL CONFERENCE 2026

Reuters·05/20/2026 12:15:00

Please log in to view news